Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients

NCT07749014 is registered in ClinicalTrials.gov with Rehman Medical Institute - RMI as lead sponsor.

NCT NCT07749014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07749014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
Lead sponsor
Rehman Medical Institute - RMI
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2027
Enrollment
480 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction (ami), coronary artery disease, st-elevation myocardial infarction (stemi)